Nebulized Amikacin: A Game-Changer for Pneumonia After Cardiac Surgery?
"New research suggests nebulized antibiotics may offer a safer, more effective alternative to IV antibiotics for treating pneumonia following heart surgery."
Pneumonia is a significant concern for patients recovering from cardiothoracic surgery. These individuals often require mechanical ventilation, which unfortunately increases the risk of developing hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). When these infections are caused by multidrug-resistant (MDR) bacteria, treatment becomes even more challenging.
Traditional treatment approaches often involve intravenous (IV) antibiotics. However, a recent study has explored the potential of nebulized antibiotics as an adjunctive therapy. Nebulized antibiotics deliver medication directly to the lungs, potentially achieving higher concentrations at the site of infection while minimizing systemic side effects.
This article delves into a study comparing the efficacy and safety of nebulized versus IV amikacin, a powerful antibiotic, in post-cardiac surgery patients with pneumonia caused by MDR Gram-negative bacteria. We’ll explore the findings, implications, and what this could mean for future treatment strategies.
Emerging Evidence and Clinical Impact
Nebulized amikacin is being studied for pneumonia prevention and treatment in mechanically ventilated patients, although available delivery and pharmacokinetic knowledge has mainly come from in vitro work and studies involving limited numbers of patients. A 2021 study evaluated nebulized amikacin as adjunctive therapy to systemic antibiotics for gram-negative pneumonia in ventilated patients. In the 2023 NEJM trial, a first episode of ventilator-associated pneumonia caused by gram-negative bacteria susceptible to amikacin occurred in 31 patients (7%) receiving inhaled amikacin and 61 patients (14%) in the comparison group.
Adjunctive Treatment and Evidence Gaps
The studied approach combines inhaled amikacin with intravenous standard-of-care antibiotics for pneumonia caused by Gram-negative pathogens in intubated, mechanically ventilated patients. One review describes evidence across hospital-acquired pneumonia, ventilator-associated pneumonia, nontuberculous mycobacterial lung disease, and cystic fibrosis, while examining efficacy, safety, resistance development, and limitations. These sources reflect an adjunctive strategy rather than a replacement for established systemic treatment, with important uncertainties remaining about effectiveness, safety, and resistance.
From Aminoglycoside to Inhaled Therapy
Amikacin is an aminoglycoside antibiotic used for serious infections caused by Gram-negative bacteria, particularly infections resistant to other antibiotics. More recent work has examined whether nebulized amikacin can extend its role into ventilator-associated pneumonia. A 2024 chapter describes a comparative study of combined intravenous and nebulized amikacin versus intravenous amikacin alone in mechanically ventilated patients with ventilator-associated pneumonia.
Nebulized vs. IV Amikacin: What the Study Revealed
A prospective, randomized, controlled study was conducted involving patients recovering from cardiothoracic surgery who developed HAP or VAP caused by MDR Gram-negative bacteria. The participants were divided into two groups: one receiving IV amikacin and the other receiving nebulized amikacin, both in addition to IV piperacillin/tazobactam. Researchers then compared several outcomes, including:
- Clinical Cure Rates: Patients receiving nebulized amikacin showed significantly higher clinical cure rates compared to those receiving IV amikacin.
- ICU Stay: The nebulized group experienced shorter stays in the intensive care unit.
- Time to Clinical Cure: Nebulized amikacin led to a faster recovery, with patients reaching clinical cure in fewer days.
- Ventilator Dependence: Patients in the nebulized group required fewer days on mechanical ventilation.
- Nephrotoxicity: Nebulized amikacin was associated with less kidney damage, as indicated by preserved kidney function and lower rates of acute kidney injury (AKI).
Recent Trials and Meta-Analyses
A systematic review and meta-analysis of inhaled antibiotics reported improved microbiological eradication across 20 randomized controlled trials involving 1,805 patients, with a risk ratio of 1.42 (95% CI, 1.27-1.58). The same analysis reported reduced emergence of new drug resistance in four randomized controlled trials involving 182 patients, with a risk ratio of 0.20 (95% CI, 0.06-0.64). A 2026 systematic review of inhaled antibiotics in children with ventilator-associated pneumonia identified seven articles involving 346 patients, including four randomized controlled trials.
Limited Certainty and Selective Use
The Infectious Diseases Society of America suggests both inhaled and systemic antibiotics for ventilator-associated pneumonia caused by Gram-negative bacilli susceptible only to aminoglycosides or polymyxins, but grades this as a weak recommendation based on very low-quality evidence. A 2024 review presents inhaled antibiotics as a potential approach, especially for cystic fibrosis and ventilator-associated pneumonia, rather than as universally established therapy. The literature also includes a study by Chen examining aerosolized amikacin in elderly patients with ventilator-associated pneumonia, illustrating that clinical evidence spans specific patient populations and study designs.
Nebulized Versus Intravenous Amikacin
A study of critical patients identified mechanical ventilation duration and nutrition support as risk factors for ventilator-associated pneumonia. Separate research evaluated nephrotoxicity associated with gentamicin or amikacin therapy in 124 patients. In postcardiothoracic surgical patients with nosocomial pneumonia caused by multidrug-resistant Gram-negative bacilli, a comparison of nebulized and intravenous amikacin focused on whether high local concentrations and minimal blood levels could provide efficacy with less nephrotoxicity; one report concluded that nebulized amikacin was more effective and less nephrotoxic, while also noting limitations that restrict the utility of those findings.
The Future of Pneumonia Treatment After Surgery?
This study provides compelling evidence for the potential benefits of nebulized amikacin in treating pneumonia following cardiothoracic surgery. While further research is always warranted, these findings suggest a promising avenue for improving patient outcomes, reducing hospital stays, and minimizing the risk of antibiotic-related complications. As antibiotic resistance continues to rise, exploring alternative delivery methods like nebulization becomes increasingly important. Nebulized amikacin may offer a valuable tool in the fight against MDR infections, particularly in vulnerable patient populations.
A Promising but Unsettled Adjunct
A 2021 systematic review and meta-analysis reported an advantage for nebulized amikacin as adjunctive treatment of gram-negative pneumonia in mechanically ventilated patients without an additional risk of nephrotoxicity. This supports considering nebulized amikacin as a targeted addition to systemic therapy rather than assuming it should replace intravenous antibiotics. However, the broader evidence base remains dependent on studies with differing populations and designs, so the reported benefit should be interpreted alongside the limitations of the underlying research.